Published in Blood Weekly, March 31st, 2005
According to a study from Germany, "fifteen patients with refractory acute myeloid leukemia (AML) were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine kinase 3 (Flt3), Kit, vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) receptors."
"Separate cohorts of patients received SU11248 for 4-week cycles followed by either a 2- or a 1 -week rest period. At the starting dose level of 50 mg (n=13), no dose-limiting toxicities were observed. The most frequent grade 2 toxicities were edema, fatigue, and oral...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.